• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

cCAM Biotherapeutics

edit

cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM’s lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient’s immune system to attack tumors. CM-10 binds CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 abrogates this effect, leading to a cancer specific immune response in patients.

Recent Milestones

edit

• 
  cCAM Biotherapeutics received () in Series A funding. (9/15/12)
  Posted 9/14/12 at 9:18pm via yahoo.com

Videos

Screenshots

edit

Above: cCAM Biotherapeutics
Uploaded: 9/15/12

Sources

1. cCAM Biotherapeutics Announced Today the Completion of its Series A Financing (finance.yahoo.com) [edit]